Nightstar plans $86 million US offering

Nightstar Therapeutics Ltd plans to raise up to $86 million in an initial public offering (IPO) of its shares on Nasdaq to advance its portfolio of gene therapies to treat rare inherited retinal diseases. A registration document was filed with the US Securities and Exchange Commission on 31 August.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom